Join
Live feed
·
PRReleasevia Quantisnow
Rapport Therapeutics Inc. logo

Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025

ByQuantisnow·Wall Street's wire, on your screen.
RAPP· Rapport Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RAPP (Rapport Therapeutics Inc.) and more on Quantisnow.